ASCENDIS PHARMA A/S - ADR (ASND) Stock Fundamental Analysis
USA - NASDAQ:ASND - US04351P1012 - ADR
202 USD
+0.99 (+0.49%)
205.4 USD
+3.4 (+1.68%)
Overall ASND gets a fundamental rating of 3 out of 10. We evaluated ASND against 534 industry peers in the Biotechnology industry. ASND may be in some trouble as it scores bad on both profitability and health. ASND is valued quite expensive, but it does show an excellent growth.
1. Profitability
1.1 Basic Checks
In the past year ASND has reported negative net income.
ASND had a negative operating cash flow in the past year.
ASND had negative earnings in each of the past 5 years.
In the past 5 years ASND always reported negative operating cash flow.
1.2 Ratios
With a decent Return On Assets value of -24.92%, ASND is doing good in the industry, outperforming 73.03% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -24.92% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-47.96%
ROA(5y)-44.4%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
ASND's Gross Margin of 84.88% is amongst the best of the industry. ASND outperforms 87.64% of its industry peers.
ASND's Gross Margin has improved in the last couple of years.
The Profit Margin and Operating Margin are not available for ASND so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 84.88% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y17.06%
GM growth 5YN/A
2. Health
2.1 Basic Checks
ASND does not have a ROIC to compare to the WACC, probably because it is not profitable.
ASND has more shares outstanding than it did 1 year ago.
The number of shares outstanding for ASND has been increased compared to 5 years ago.
The debt/assets ratio for ASND has been reduced compared to a year ago.
2.2 Solvency
ASND has an Altman-Z score of 1.23. This is a bad value and indicates that ASND is not financially healthy and even has some risk of bankruptcy.
ASND has a Altman-Z score of 1.23. This is in the better half of the industry: ASND outperforms 62.36% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1.23 |
ROIC/WACCN/A
WACC6.69%
2.3 Liquidity
A Current Ratio of 1.02 indicates that ASND should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.02, ASND is doing worse than 87.08% of the companies in the same industry.
A Quick Ratio of 0.69 indicates that ASND may have some problems paying its short term obligations.
Looking at the Quick ratio, with a value of 0.69, ASND is doing worse than 90.45% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.02 | ||
| Quick Ratio | 0.69 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 46.93% over the past year.
Looking at the last year, ASND shows a very strong growth in Revenue. The Revenue has grown by 54.50%.
ASND shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 93.57% yearly.
EPS 1Y (TTM)46.93%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%66.49%
Revenue 1Y (TTM)54.5%
Revenue growth 3Y260.22%
Revenue growth 5Y93.57%
Sales Q2Q%339.04%
3.2 Future
Based on estimates for the next years, ASND will show a very strong growth in Earnings Per Share. The EPS will grow by 39.24% on average per year.
The Revenue is expected to grow by 56.96% on average over the next years. This is a very strong growth
EPS Next Y59.37%
EPS Next 2Y58.96%
EPS Next 3Y50.46%
EPS Next 5Y39.24%
Revenue Next Year131.74%
Revenue Next 2Y102.21%
Revenue Next 3Y79.17%
Revenue Next 5Y56.96%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
ASND reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
A Price/Forward Earnings ratio of 50.34 indicates a quite expensive valuation of ASND.
Based on the Price/Forward Earnings ratio, ASND is valued cheaper than 89.33% of the companies in the same industry.
ASND's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 22.92.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 50.34 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
ASND's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as ASND's earnings are expected to grow with 50.46% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y58.96%
EPS Next 3Y50.46%
5. Dividend
5.1 Amount
ASND does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
202
+0.99 (+0.49%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners105.14%
Inst Owner Change-0.09%
Ins Owners0.78%
Ins Owner ChangeN/A
Market Cap12.22B
Revenue(TTM)490.75M
Net Income(TTM)-271148000
Analysts87.27
Price Target254.36 (25.92%)
Short Float %4.35%
Short Ratio5.94
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)23.02%
Min EPS beat(2)-3.72%
Max EPS beat(2)49.75%
EPS beat(4)3
Avg EPS beat(4)20.91%
Min EPS beat(4)-3.72%
Max EPS beat(4)49.75%
EPS beat(8)4
Avg EPS beat(8)0.61%
EPS beat(12)6
Avg EPS beat(12)-0.9%
EPS beat(16)9
Avg EPS beat(16)4.54%
Revenue beat(2)2
Avg Revenue beat(2)7.02%
Min Revenue beat(2)4.58%
Max Revenue beat(2)9.46%
Revenue beat(4)3
Avg Revenue beat(4)6.33%
Min Revenue beat(4)-31.16%
Max Revenue beat(4)42.44%
Revenue beat(8)5
Avg Revenue beat(8)12.17%
Revenue beat(12)9
Avg Revenue beat(12)21.39%
Revenue beat(16)12
Avg Revenue beat(16)23.77%
PT rev (1m)0%
PT rev (3m)7.29%
EPS NQ rev (1m)1.24%
EPS NQ rev (3m)60.9%
EPS NY rev (1m)20.02%
EPS NY rev (3m)36.49%
Revenue NQ rev (1m)-0.43%
Revenue NQ rev (3m)17.54%
Revenue NY rev (1m)0%
Revenue NY rev (3m)14.17%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 50.34 | ||
| P/S | 21.48 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-5.31
EYN/A
EPS(NY)4.01
Fwd EY1.99%
FCF(TTM)-3.27
FCFYN/A
OCF(TTM)-3.16
OCFYN/A
SpS9.4
BVpS-3.59
TBVpS-3.67
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -24.92% | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 84.88% | ||
| FCFM | N/A |
ROA(3y)-47.96%
ROA(5y)-44.4%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y17.06%
GM growth 5YN/A
F-Score4
Asset Turnover0.45
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 33.48% | ||
| Cap/Sales | 1.21% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.02 | ||
| Quick Ratio | 0.69 | ||
| Altman-Z | 1.23 |
F-Score4
WACC6.69%
ROIC/WACCN/A
Cap/Depr(3y)33.9%
Cap/Depr(5y)97.41%
Cap/Sales(3y)9.88%
Cap/Sales(5y)130.23%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)46.93%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%66.49%
EPS Next Y59.37%
EPS Next 2Y58.96%
EPS Next 3Y50.46%
EPS Next 5Y39.24%
Revenue 1Y (TTM)54.5%
Revenue growth 3Y260.22%
Revenue growth 5Y93.57%
Sales Q2Q%339.04%
Revenue Next Year131.74%
Revenue Next 2Y102.21%
Revenue Next 3Y79.17%
Revenue Next 5Y56.96%
EBIT growth 1Y30.39%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year53.32%
EBIT Next 3Y58.81%
EBIT Next 5YN/A
FCF growth 1Y68.88%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y69.49%
OCF growth 3YN/A
OCF growth 5YN/A
ASCENDIS PHARMA A/S - ADR / ASND FAQ
Can you provide the ChartMill fundamental rating for ASCENDIS PHARMA A/S - ADR?
ChartMill assigns a fundamental rating of 3 / 10 to ASND.
What is the valuation status of ASCENDIS PHARMA A/S - ADR (ASND) stock?
ChartMill assigns a valuation rating of 2 / 10 to ASCENDIS PHARMA A/S - ADR (ASND). This can be considered as Overvalued.
What is the profitability of ASND stock?
ASCENDIS PHARMA A/S - ADR (ASND) has a profitability rating of 2 / 10.
What is the financial health of ASCENDIS PHARMA A/S - ADR (ASND) stock?
The financial health rating of ASCENDIS PHARMA A/S - ADR (ASND) is 1 / 10.